Efficacy of atypical antipsychotics in the treatment of fecal incontinence in children and adolescents: a randomized clinical trial

• Published in: BMC pediatrics Vol. 24; no. 1; p. 7
• Main Authors: Zahed, Ghazal, Fatahi, Somaye, Tabatabaee, Leila, Imanzadeh, Negar, Seraj, Shaikh Sanjid, Wolters, Benjamin Hernández, Hosseini, Amirhossein
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 03-01-2024; BioMed Central; BMC
• Subjects: Adolescent; Age; Antipsychotic Agents - therapeutic use; Antipsychotics; Anxiety; Attention deficit hyperactivity disorder; Atypical antipsychotics; Child; Child, Preschool; Children; Children & youth; Clinical trials; Comorbidity; Constipation; Demographic aspects; Dextrins; Dopamine; Dosage and administration; Drug therapy; Encopresis; Evaluation; Families & family life; Fecal incontinence; Fecal Incontinence - chemically induced; Fecal Incontinence - drug therapy; Fecal Incontinence - epidemiology; Fecal soiling; Feces; Health aspects; Humans; Intervention; Mental disorders; Mental illness; Methods; Pediatric; Pediatrics; Retentive fecal incontinence; Risperidone; Risperidone - therapeutic use; Standard scores; Teenagers; Youth; Iran; Retentive fecal incontinence; Atypical antipsychotics; Risperidone; Pediatric; Fecal soiling; Encopresis
• ISSN: 1471-2431; 1471-2431
• DOI: 10.1186/s12887-023-04474-4

Functional retentive overflow incontinence (retentive FI) is the most common cause of fecal soiling in children. Based on the clinical experiences, the treatment of retentive FI in patients with comorbid psychiatric disorders was accelerated when Risperidone was used as treatment for their psychiatric comorbidities; therefore, this study was conducted to evaluate the effect of risperidone in the treatment of retentive FI in children and adolescents.
In this double-blind, randomized, placebo-controlled trial, 140 patients aged 4-16 years eligible for the study were randomized into two groups, receiving either 0.25-0.5 mg of Risperidone syrup (n = 70) or maltodextrin syrup (placebo group, n = 70) every 12 h daily for 12 weeks. Sociodemographic data, including age, sex, weight, height, BMI, BMI z-score, and socioeconomic status, was recorded, and the number of nocturnal FI, diurnal FI, and painful defecations was measured.
136 participants (69 on Risperidone and 67 on placebo) were included in the study. Mean age of participants in the intervention and placebo groups were 7.2 ± 2.4 years and 8.0 ± 3.1 years, respectively. The mean number of nocturnal FI (P
=0.39) and diurnal FI (P
=0.48) in patients without psychiatric comorbidities, and the number of painful defecations for participants with and without psychiatric comorbidities (P = 0.49, P = 0.47, respectively) were not significantly different between the groups, but a significant effect was observed in diurnal FI after Risperidone treatment in patients with psychiatric comorbidities (P < 0.001).
Risperidone, when used along with other non-pharmacological interventions, may be helpful in treating FI in pediatric patients with psychiatric comorbidities.